Mantis Biotech vs Genentech

Side-by-side comparison of AI visibility scores, market position, and capabilities

Genentech leads in AI visibility (72 vs 34)
Mantis Biotech logo

Mantis Biotech

EmergingBioTech

AI Clinical Trial Simulation

YC-backed AI company raised $48M Series A co-led by a16z Bio and GV in Feb 2026; builds digital twins of human physiology to generate diverse synthetic clinical trial populations, addressing chronic underrepresentation of women and minorities.

AI VisibilityBeta
Overall Score
D34
Category Rank
#162 of 198
AI Consensus
90%
Trend
stable
Per Platform
ChatGPT
35
Perplexity
36
Gemini
33

About

Mantis Biotech is a YC-backed AI company that builds digital twins of human physiology to synthesize diverse, realistic clinical trial populations. The company addresses one of drug development's most persistent problems: clinical trials consistently underrepresent women, elderly patients, and minorities, producing efficacy data that fails to predict real-world outcomes across populations. Mantis's AI platform generates synthetic patient data that fills these representation gaps.

Full profile
Genentech logo

Genentech

LeaderLife Sciences & BioTech

Biopharmaceuticals

Roche subsidiary and founding biotech; invented the biologics industry with recombinant DNA. Blockbuster oncology franchise includes Herceptin, Avastin, Rituxan, and Tecentriq.

AI VisibilityBeta
Overall Score
B72
Category Rank
#17 of 198
AI Consensus
76%
Trend
stable
Per Platform
ChatGPT
74
Perplexity
72
Gemini
66

About

Genentech was founded in 1976 in South San Francisco by Herbert Boyer and Robert Swanson, becoming the first company to produce human insulin using recombinant DNA technology and essentially launching the modern biotechnology industry. Acquired by Roche in 2009 for $46.8 billion, Genentech continues to operate with significant R&D autonomy as the US hub for Roche's pharmaceutical innovation.\n\nThe company is best known for pioneering cancer biologics, developing Herceptin (trastuzumab) for HER2-positive breast cancer, Avastin (bevacizumab) for multiple cancers, Rituxan (rituximab) for lymphoma, and Tecentriq (atezolizumab) for PD-L1 immunotherapy. Its discovery engine spans oncology, neuroscience, ophthalmology, and immunology with a robust early-stage pipeline leveraging AI-assisted target identification.\n\nGenentech generates tens of billions in annual revenue through Roche's Pharmaceuticals Division and remains one of the most productive biotech research sites in the world, consistently ranked among top employers in life sciences. The South San Francisco campus employs over 13,000 scientists, clinicians, and engineers, anchoring the Bay Area as a global biotech hub.

Full profile

AI Visibility Head-to-Head

34
Overall Score
72
#162
Category Rank
#17
90
AI Consensus
76
stable
Trend
stable
35
ChatGPT
74
36
Perplexity
72
33
Gemini
66
34
Claude
75
32
Grok
68

Key Details

Category
AI Clinical Trial Simulation
Biopharmaceuticals
Tier
Emerging
Leader
Entity Type
brand
company

Capabilities & Ecosystem

Capabilities

Only Mantis Biotech
AI Clinical Trial Simulation
Only Genentech
Biopharmaceuticals
Genentech is classified as company.

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.